42 Myalgic Encephalomyelitis Clinical Trials in Nashville, TX (2026)

Q: How do I join a clinical trial in Nashville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you.

Recruiting Myalgic Encephalomyelitis Studies in Nashville

NCT05372159Recruiting

Vanderbilt Memory and Aging Project

This study will use an observational cohort to cross-sectionally and longitudinally relate vascular health to clinical, imaging, and biological markers of early Alzheimer's disease and cerebrovascular...

Nashville, TX1,000 participantsVanderbilt University Medical Center

View Study Details

NCT01376024Recruiting

Study on Basal Joint Arthritis Prospective

The data in this prospective registry will be used 1) to define which surgical and nonoperative techniques are most effective at providing pain relief, restoring function, are cost effective, and pati...

Nashville, TX800 participantsColumbia University

View Study Details

NCT03966872Recruiting

Comparative Effectiveness of IIMR Versus CDSMP

The study will enroll 600 people with serious mental illness who receive services at Centerstone in KY or TN and will compare two different evidence-based self-management interventions: Integrated Ill...

Nashville, TX600 participantsDartmouth-Hitchcock Medical Center

View Study Details

NCT07146516Recruiting

Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)

The goal of this clinical trial is to prospectively document to what extent the OSC/SS prophylactic laser retinopexy procedure works to prevent retinal detachment in SS in children and adults. Resear...

Nashville, TX500 participantsHelen Keller Eye Research Foundation

View Study Details

NCT05581004Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizum...

Nashville, TX450 participantsGenentech, Inc.

View Study Details

NCT07287995Recruiting

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then att...

Nashville, TX428 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT07066657Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic...

Nashville, TX405 participantsArriVent BioPharma, Inc.

View Study Details

NCT07154290Recruiting

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if i...

Nashville, TX300 participantsRegeneron Pharmaceuticals

View Study Details

NCT07229430Recruiting

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

This is a prospective, multicenter, randomized, evaluator-blinded, parallel-controlled, non-inferiority clinical study designed to evaluate the safety and effectiveness of the ULTRAFORMER MPT PLUS, a ...

Nashville, TX273 participantsCLASSYS Inc.

View Study Details

NCT06752681Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced o...

Nashville, TX254 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT03851484Recruiting

Sensory Symptoms in Tourette Syndrome

Patients with tics will be asked to complete a series of validated questionnaires (in electronic and/or paper format) regarding symptoms and conditions often associated with Tourette syndrome, includi...

Nashville, TX214 participantsVanderbilt University Medical Center

View Study Details

NCT05932589Recruiting

Neurophysiologic Biomarkers in Rett Syndrome

The goal of this observational study is to identify candidate biomarkers in individuals with Rett Syndrome (RTT). The main questions it aims to answer are: * Do these biomarkers change during clinica...

Nashville, TX202 participantsChildren's Hospital of Philadelphia

View Study Details

NCT07021898Recruiting

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ...

Nashville, TX200 participantsErasca, Inc.

View Study Details

NCT05770531Recruiting

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

This phase II trial tests how well evaluating circulating tumor deoxyribonucleic acid (ctDNA) works to guide therapy-change decisions in treating patients with triple-negative breast cancer (TNBC) tha...

Nashville, TX160 participantsVanderbilt-Ingram Cancer Center

View Study Details

NCT05267626Recruiting

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be adminis...

Nashville, TX159 participantsAulos Bioscience, Inc.

View Study Details

NCT03328650Recruiting

Clinical Outcomes of the ALPS Proximal Humerus Plating System

The purpose of this study is to document the performance and clinical outcomes of the A.L.P.S® Proximal Humerus Plating System. Specific Aims: * Conduct physical assessments measuring shoulder stren...

Nashville, TX150 participantsVanderbilt University Medical Center

View Study Details

NCT04851678Recruiting

Longitudinal Impact of Stressors in Adults With Tourette Syndrome

The Investigators propose a two-year, longitudinal pilot study of TS adults (\>18) to determine impact of lifetime environmental stress exposure on tic severity, psychiatric comorbidity severity, and ...

Nashville, TX140 participantsVanderbilt University Medical Center

View Study Details

NCT06055439Recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least ...

Nashville, TX135 participantsChimeric Therapeutics

View Study Details

NCT05334368Recruiting

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study w...

Nashville, TX123 participantsGlaxoSmithKline

View Study Details

NCT06414460Recruiting

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability o...

Nashville, TX114 participantsInSilico Medicine Hong Kong Limited

View Study Details

NCT06566079Recruiting

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with ...

Nashville, TX100 participantsInSilico Medicine Hong Kong Limited

View Study Details

NCT07287917Recruiting

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: ...

Nashville, TX92 participantsAminex Therapeutics, Inc.

View Study Details

NCT07197944Recruiting

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Gl...

Nashville, TX90 participantsZealand Pharma

View Study Details

NCT07015697Recruiting

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors....

Nashville, TX76 participantsDaiichi Sankyo

View Study Details

NCT06994676Recruiting

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolle...

Nashville, TX72 participantsCrossbow Therapeutics, Inc.

View Study Details

NCT07142252Recruiting

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (...

Nashville, TX66 participantsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

View Study Details

NCT05187832Recruiting

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in...

Nashville, TX61 participantsKind Pharmaceuticals LLC

View Study Details

NCT07140900Recruiting

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone....

Nashville, TX60 participantsAmgen

View Study Details

NCT07189936Recruiting

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from...

Nashville, TX50 participantsVanderbilt University Medical Center

View Study Details

NCT06430385Recruiting

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

The primary purpose of this study is to evaluate the safety and tolerability of ION440....

Nashville, TX48 participantsIonis Pharmaceuticals, Inc.

View Study Details

NCT06940739Recruiting

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel....

Nashville, TX42 participantsIovance Biotherapeutics, Inc.

View Study Details

NCT05431270Recruiting

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in ...

Nashville, TX40 participantsPhanes Therapeutics

View Study Details

NCT07493512Recruiting

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC)....

Nashville, TX40 participantsAmgen

View Study Details

NCT07136181Recruiting

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body. Th...

Nashville, TX36 participantsNovelwise Pharmaceutical Corporation

View Study Details

NCT07584226Recruiting

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, a...

Nashville, TX35 participantsRelay Therapeutics, Inc.

View Study Details

NCT07524855Recruiting

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed...

Nashville, TX33 participantsHalda Therapeutics OpCo, Inc.

View Study Details

NCT07493447Recruiting

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of ...

Nashville, TX30 participantsEben Rosenthal

View Study Details

NCT07156318Recruiting

Drumming Lessons' Influence on Children With Down Syndrome

The goal of this clinical trial is to learn if drumming lessons can increase self-control in children with Down syndrome. The main question it aims to answer is whether 2 months of drumming lessons ca...

Nashville, TX30 participantsVanderbilt University

View Study Details

NCT06643884Recruiting

Suprachoroidal Administration in Subjects With Choroidal Metastasis From Breast or Lung Primary Tumors

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with choroidal metastasis from breast or lung primary tumors....

Nashville, TX24 participantsAura Biosciences

View Study Details

NCT05425004Recruiting

Cabozantinib for Patients With Recurrent or Progressive Meningioma

A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma...

Nashville, TX24 participantsBaptist Health South Florida

View Study Details

NCT06064890Recruiting

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations...

Nashville, TX18 participantsAviadoBio Ltd

View Study Details

NCT07197905Recruiting

Restoring Iron Deficiency in POTS

People with postural orthostatic tachycardia syndrome (POTS) often have low red blood cell volumes and low ferritin in their blood (a marker of iron storage in the body). The purpose of this pilot stu...

Nashville, TX12 participantsVanderbilt University Medical Center

View Study Details

About Myalgic Encephalomyelitis Clinical Trials in Nashville

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 42 myalgic encephalomyelitis clinical trials recruiting participants in Nashville, TX. These studies are seeking a combined 7,686 participants. Research is being sponsored by Vanderbilt University Medical Center, Columbia University, Dartmouth-Hitchcock Medical Center and 32 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Nashville — FAQ

Are there myalgic encephalomyelitis clinical trials in Nashville?

Yes, there are 42 myalgic encephalomyelitis clinical trials currently recruiting in Nashville, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Nashville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you about next steps.

Are clinical trials in Nashville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Nashville studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 42 active trials in Nashville are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated July 13, 2026 from ClinicalTrials.gov